-5%
Tridyl is used as an adjunctive therapy in all types of Parkinsonism, including postencephalitic, arteriosclerotic, and idiopathic forms. It is often prescribed alongside levodopa to enhance symptom control. Additionally, Tridyl is indicated for managing extrapyramidal side effects caused by central nervous system drugs such as dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones.
Trihexyphenidyl is a non-selective muscarinic acetylcholine receptor antagonist with a higher affinity for the M1 subtype. It binds more readily to central muscarinic receptors in the cerebral cortex than to peripheral ones. Research also suggests that it may influence nicotinic acetylcholine receptor activity, indirectly increasing dopamine release in the striatum. While effective in relieving symptoms of Parkinson’s disease and other movement disorders, its exact mechanism is not fully understood.
Tridyl works by directly inhibiting the parasympathetic nervous system and relaxing smooth muscles. This relaxation occurs both through a direct effect on muscle tissue and indirectly via its parasympathetic inhibition.